This haematoencephalic barrier (HEB) isolates the brain from the rest of the organism and selectively controls the passage of solutes to the CNS, letting them pass through or not. This protective function clashes with biomedicine because it is an obstacle to the successful delivery of necessary medication to the brain, for example in the treatment of illnesses such as Alzheimer or Parkinson. Thus, the need for the international pharmaceutical sector to draw up models involving the principal features of this blood-brain barrier, in order to obtain more precise and reliable predictions regarding the permeability of these pharmaceutical drugs.
This is why, since 2010, GAIKER-IK4 has been drawing up a comparative study of the most employed in vitro models of the blood-brain barrier currently in use in the sector. Their goal is to determine which is the optimum model for the reproduction of conditions in vivo, to be subsequently applied to studies in toxicology and efficacious research, in both the pharmacological and nanomedicine fields.
The project is anticipated to finish in 2013.